Endovascular Engineering
Endovascular Engineering (E2) is developing a next-generation clot removal technology platform focused on venous thromboembolism (VTE), with an initial focus on pulmonary embolism (PE). The company aims to revolutionize VTE treatment through its Hēlo™ PE Thrombectomy System, featuring a dual-action mechanism for efficient clot removal. E2's mission is to advance the standard of care in clot removal with its innovative technology platform.
Funding Round: Series B
Funding Amount: $42M
Date: 18-Feb-2025
Investors: 415 Capital, S3 Ventures, Panakès Partners, M&L Healthcare, Santè Ventures, Cordis
Markets: Healthtech, Medical Devices, Clinical Trials, Medical, Medical Device
HQ: Menlo Park, California, United States
Founded: 2019
Website: https://endovascularengineering.com/
LinkedIn: https://www.linkedin.com/company/endovascular-engineering
Crunchbase: https://www.crunchbase.com/organization/endovascular-engineering
Leave a Comment
Comments
No comments yet.